If your knees ache in the morning and you’ve been told omega-3s might help, you’ve probably ended up staring at two bottles in the supplement aisle: fish oil, which is cheap and everywhere, and krill oil, which costs more and promises to be the smarter molecule. The question you’re really asking is simple. For a sore joint, does the more expensive one earn its price?
I sell krill oil for a living, so you’d expect me to tell you it does. Instead I’m going to walk you through what the trials actually found, including the one I’d least like to talk about — a large, well-run 2024 study that tested krill oil for exactly this purpose and came up empty. The honest answer is that the science here is genuinely mixed, there is no clean head-to-head trial pitting krill against fish oil for joint pain, and the gap between the two forms is almost certainly smaller than the marketing on either bottle would have you believe.
Here’s the longer version, because the details are where the real answer lives.
First, the uncomfortable part: there’s no true head-to-head trial
People search “krill oil vs fish oil for joints” expecting that somewhere, someone ran the obvious experiment — same people, same joints, half on krill and half on fish oil, and measured who hurt less. As far as the published literature goes, that trial doesn’t exist. What we have instead is a scatter of separate studies: some testing krill oil against a placebo, some testing fish oil against a placebo, and a handful comparing how much omega-3 each one gets into your blood. To answer the comparison question, you have to lay those studies side by side and reason across them, which is a weaker kind of evidence than a direct contest. Anyone who tells you krill “beats” fish oil for joints is extrapolating, not quoting a result. Keep that in mind for the rest of this, including the parts where I’m doing the same thing.
What the krill oil joint trials actually found
Krill oil has been tested against placebo for knee pain three notable times, and the results don’t line up as neatly as I’d like.
The first, a small 2016 randomized trial in adults with mild knee pain, found that 2 grams a day improved pain during sleep and standing over 30 days. Encouraging, but small and short.
Then came the study krill’s defenders love to cite: a 2022 multicenter trial published in the American Journal of Clinical Nutrition00084-3/fulltext) (Stonehouse et al.), 235 adults with mild-to-moderate knee osteoarthritis, 4 grams of krill oil a day for six months. It found statistically significant improvements in WOMAC scores for stiffness, physical function, and total knee score versus a placebo oil. Notably, the people who improved the most were those who started with the highest inflammation, measured by elevated baseline CRP — a clue that omega-3s may do more for an inflamed joint than a merely worn one. This was, at the time, the largest and most rigorous krill-for-knees study on record, and it was a genuine win.
And then came the one I owe you. In 2024, a team at Monash University published a 262-person trial in JAMA — patients with clinical knee osteoarthritis who had real pain and visible inflammation (effusion-synovitis) on MRI, given 2 grams of krill oil a day for 24 weeks. The result: no improvement in knee pain over placebo. The mean difference on a 100-point pain scale was 0.3 points, with a P value of 0.94, which in plain English means the two groups were indistinguishable. The authors concluded the data “does not support” krill oil at that dose for this population.
So one large positive trial, one large negative trial, in the same disease, a couple of years apart. What separates them? Probably three things: the negative trial used a lower dose (2 grams vs. 4), it deliberately enrolled people with more advanced, visibly inflamed joints, and the placebo group happened to improve a lot on its own — which is maddeningly common in pain research. None of that lets me wave the 2024 result away. The most you can honestly say is that krill oil may help milder, inflammation-driven knee pain at a high enough dose, and that the evidence is far from settled. A newer 2025–2026 pilot study is now testing 4 grams a day in older adults with more severe chronic pain, mostly to establish whether people will stick with that dose — which tells you the researchers themselves think dose and adherence are the open questions.
What fish oil’s own joint evidence looks like
Fish oil doesn’t get a free pass here either. Its evidence for osteoarthritis is in roughly the same boat: suggestive, inconsistent, and limited by small, biased studies.
A 2023 meta-analysis in the Journal of Orthopaedic Surgery and Research pooled the omega-3 osteoarthritis trials and concluded that supplementation does help relieve pain and improve joint function — but flagged that the underlying evidence is low quality, drawn from only a handful of trials with a high risk of bias. A separate 2020 trial in Rheumatology Advances in Practice found that DHA-rich fish oil reduced osteoarthritis-specific pain in overweight, sedentary older adults over 16 weeks. And a thoughtful 2024 review in Arthritis Care & Research by Felson and colleagues looked across the essential-fatty-acid-and-osteoarthritis literature and landed on a cautious “maybe, for some people, modestly” — which is about the most honest summary anyone has offered.
One detail worth carrying forward: across this research, EPA appears to be the omega-3 with the strongest anti-inflammatory effect. That matters because EPA-to-DHA ratios differ between products, and a high-EPA fish oil concentrate may, on the inflammation front, have an edge that has nothing to do with whether the oil came from a fish or a krill.
The bioavailability argument — and why it matters less for joints than the label implies
Here’s where krill oil’s marketing does its heaviest lifting. Krill oil carries its EPA and DHA in phospholipid form, while standard fish oil carries them as triglycerides or ethyl esters. Phospholipids mix more readily into the watery contents of your gut, so they tend to absorb a bit more efficiently. A network meta-analysis published in October 2024 supports this: across dozens of studies, the phospholipid form showed superior absorption, especially at lower doses.
That’s a real advantage — but notice what it is and isn’t. “More efficiently absorbed per milligram” is not the same as “more total omega-3 in your blood.” Krill oil bottles usually contain less EPA and DHA per gram than concentrated fish oil, so the absorption edge often just offsets the lower payload. In fact, a separate dose-matched trial found no difference in the EPA and DHA your red blood cells end up with after four weeks of krill versus fish oil. For your joints specifically — which care about how much omega-3 reaches the tissue over months, not how slickly it crossed the gut wall on day one — the phospholipid story is more elegant than it is decisive. It’s a reason to consider krill, not a reason to be certain about it.
The lever that actually moves the needle: dose and consistency
Strip away the form wars and a quieter pattern emerges from all of these trials. The studies that worked tended to use real doses — 2 to 4 grams of oil daily, often delivering well over a gram of combined EPA and DHA — taken consistently for months. Omega-3s are not aspirin. They don’t switch off a sore joint in an afternoon; they slowly shift the balance of inflammatory signaling, and that takes 8 to 12 weeks of not missing days before you can fairly judge whether it’s doing anything.
This is the unglamorous truth that both industries would rather not lead with: the person who takes a cheap fish oil every single morning for three months will almost certainly do better than the person who buys a premium krill oil and remembers it twice a week. Whatever modest benefit omega-3s offer your joints, it is entirely hostage to whether you actually keep taking them. That, and not the molecular form, is where most people lose the benefit.
So which should you take?
If you’ll take either one faithfully, the honest expectation is similar — a modest improvement for some people, especially if your joint pain is inflammation-driven and your starting omega-3 intake is low, and little to nothing for others. That’s not a satisfying answer, but it’s the true one.
Where the choice genuinely tilts toward krill oil is tolerability. The most common reason people quit fish oil is the fishy reflux and aftertaste, and krill oil’s phospholipid form tends to cause far less of it. If burps are what’s stopping you from being consistent, then krill solves the only problem that actually matters — it gets you to keep taking it. Where the choice tilts toward fish oil is cost and dose: if you need a high daily gram-count of EPA and DHA and price is a constraint, a concentrated fish oil delivers more omega-3 per dollar, and consistency is easier to afford. And if your pain is significant and persistent, the most useful thing this article can tell you isn’t which oil to buy — it’s to talk to a clinician about whether omega-3s belong in your plan at all, because for advanced osteoarthritis the 2024 trial is a real cautionary note.
A note on Captains
We make a krill oil, so you’d be right to read everything above with a raised eyebrow. But the reason I’ll point you to the 2024 null result instead of burying it is the same reason our oil is mechanically extracted with no chemical solvents at any stage and ships with a full certificate of analysis for every batch: if we’re going to ask you to trust what’s in the bottle, we have to be straight about what it can and can’t do. Krill oil is a clean, well-absorbed, easy-to-tolerate way to get your omega-3s, and for the right person with the right joint, it may help. It is not a cure for an arthritic knee, and anyone selling it as one is selling you something we won’t. Honest answer, not a pitch. — captainskrilloil.com